Eli Lilly to continue other COVID-19 antibody drug trials after pausing one on safety concerns

Related

Eli Lilly & Co on Wednesday said that other trials of its experimental COVID-19 antibody drug will continue apace after it paused one ongoing trial of the drug, citing safety concerns.

The paused trial, which Lilly calls ACTIV-3, focused on hospitalized patients. Lilly said it differed from its other trials in some key respects, including the fact that the patients had more serious illness and were being treated with other drugs, including Gilead Sciences Inc’s remdesivir.

(Reporting by Carl O’Donnell; Editing by Chizu Nomiyama)

- Advertisement -
SourceReuters

Add your comment(s)

 

Latest

Pakistani PM writes to Facebooks Zuckerberg seeking ban on Islamophobic content

Pakistani Prime Minister Imran Khan has written a letter to Facebook CEO Mark Zuckerberg seeking a ban on Islamophobic content on the social networking...

Trump goes on offensive against Biden with trip to New Hampshire

By Steve Holland President Donald Trump will go on the offensive against Democratic rival Joe Biden on Sunday with a campaign trip to New Hampshire,...

Cenovus Energy to buy Husky Energy in an all-stock deal valued at $23.6 billion

Cenovus Energy Inc will buy Husky Energy Inc in an all-stock transaction valued at $23.6 billion, the companies said in a statement on Sunday. Husky...

Pence’s staff at White House test positive for COVID-19

By Lisa Shumaker A new coronavirus outbreak at the White House involving Vice President Mike Pence's staff comes as the United States reported a near-record...

Belarus police fire stun grenades at protesters as opposition threatens national strike

Belarusian police used stun grenades against protesters on Sunday as tens of thousands of people headed towards Independence Palace in the capital Minsk demanding...

Trending